Innovative clinical trial design is a new paradigm in breast cancer research

Share this article:

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013.

The research initiative, investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2—called I-SPY 2—employs an innovative clinical trial design in the curative setting that is enabling researchers to quickly stop drugs and drug combinations that do not work, while fast-tracking effective regimens for further study.

The first drug to graduate out of this innovative research design is veliparib, which was added to standard chemotherapy (carboplatin and paclitaxel) given to women with high-risk breast cancer. Kathy Albain, MD, of Loyola University Medical Center in Maywood, Illinois, is among the coauthors of the trial, and Loyola enrolled patients in the trial.

In a traditional clinical trial of treatment after definitive breast cancer surgery, the veliparib/carboplatin/paclitaxel regimen would have been tested on a very large and broad population of high-risk patients whose tumors are designated as human epidermal growth factor receptor 2 (HER2)-negative (in an HER2-negative tumor, the cancer cells do not have a surface receptor protein known as HER2).

In I-SPY 2, women received the veliparib/carboplatin/paclitaxel combination prior to surgery, and response rates to the drugs were determined by examining tumor specimens removed during surgery. Researchers then used a statistical model to predict which subset of patients would most likely benefit in a small follow-up phase 3 clinical trial. In this way, new drugs can get to patients much faster than in the traditional approach.

In this trial, researchers estimated that the subset of patients with triple-negative breast cancer had the greatest benefit from the addition of veliparib, as well as a 91% probability of success in the confirmatory small phase 3 trial. (Triple negative means that HER2, estrogen, or progesterone receptors are not present on cancer cells.)

By comparison, there was only a 70% probability of success for all HER2-negative patients and only a 16% probability of success for HER2-negative patients whose cancer cells showed estrogen or progesterone.

Researchers concluded that the veliparib/carboplatin/paclitaxel regimen should be further tested in the confirmatory phase 3 trial, but only in patients with triple-negative breast cancer. The innovative I-SPY 2 design enabled researchers to make this recommendation based on a modest number of subjects—72 patients who received veliparib/carboplatin/paclitaxel, and 62 patients who were randomly assigned to a control group without veliparib.

"I-SPY 2 is a new paradigm in breast cancer clinical trials," Albain said. "The veliparib/carboplatin/paclitaxel study is a great example of how I-SPY 2 can tell us, as rapidly as possible, which drugs work best on different types of tumors. This could prove to be an enormous benefit to patients, especially women with the most aggressive cancers."

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.